Quick Facts: Main Therapeutic Domains

• Aims to manage elevated blood lipid levels.
• Used in mixed dyslipidemia characterized by high triglycerides and low HDL-cholesterol.
• Employed when LDL-cholesterol is already adequately controlled on a statin alone.

---

Pravafenix is a combination treatment used as an adjunctive measure to diet and other non-pharmacological interventions, such as exercise and weight reduction. It is prescribed to adult patients who have mixed dyslipidemia. This condition involves a combination of lipid abnormalities, specifically elevated triglyceride levels and reduced levels of High-Density Lipoprotein cholesterol (HDL-C), often referred to as 'good' cholesterol.

The use of this medication is typically reserved for those who are considered to be at high cardiovascular risk, where Low-Density Lipoprotein cholesterol (LDL-C) levels are already managed by the pravastatin component. The fenofibrate component is intended to influence the remaining lipid parameters to achieve overall therapeutic goals. The aim of therapy is to help reduce the concentration of triglycerides and to promote an increase in HDL-C levels.

This approach to management is part of a broader strategy to support the normalization of blood lipid profiles in specific patient populations.

Regulatory References

1. EMA therapeutic overview for Pravafenix

Who can and cannot use Pravafenix (Fenofibrate/Pravastatin)?

Pravafenix is officially restricted to adult patients with mixed dyslipidemia whose LDL-C (bad cholesterol) is already adequately controlled on a statin alone. Eligibility and non-eligibility are strictly defined by regulatory documents based on age, reproductive status, and pre-existing organ conditions.

---

Contraindicated Populations (Must Not Use)

Population/Condition	Regulatory Status
Children and Adolescents (Under 18)	Contraindicated
Pregnancy and Lactation	Contraindicated
Severe Hepatic Impairment or Active Liver Disease	Contraindicated
Moderate or Severe Renal Impairment (CrCl < 60 mL/min)	Contraindicated
History of Myopathy or Rhabdomyolysis	Contraindicated
Pre-existing Gallbladder Disease	Contraindicated

---

Restricted or Conditional Use

Use is not recommended in patients with moderate hepatic impairment. Caution is required for patients with mild renal impairment (CrCl ge 60 mL/min), which necessitates systematic renal function assessment. Additional caution is mandated for patients aged 70 years or older with risk factors for muscle toxicity, such as uncontrolled hypothyroidism or a history of alcohol abuse.

Interactions with other medicines and products

The interaction profile of Pravafenix (Fenofibrate/Pravastatin) is strictly defined by regulatory authorities based on documented pharmacokinetic (PK) and pharmacodynamic (PD) interference, establishing formal constraints on co-administration.

Interaction Classifications

Classification	Interacting Agents
Contraindicated Combination	Systemic fusidic acid (requires mandatory discontinuation of the statin component for seven days after stopping fusidic acid).
Additive PD Toxicity	Other Fibric acid derivatives (e.g., Gemfibrozil), Colchicine, and HMG-CoA Reductase Inhibitors (Statins) due to increased risk of myopathy and rhabdomyolysis.
Exposure Modification	Bile acid binding resins (e.g., Colestyramine) reduce the bioavailability of the Pravastatin component by up to 50%. Immunosuppressants (e.g., Cyclosporine) may increase Fenofibrate exposure.

---

Official Regulatory Statements

Co-administration with Coumarin anticoagulants requires caution, as the fenofibrate component causes a documented potentiation of their effect, necessitating maintenance of PT/INR stability. The Pravastatin component is not significantly metabolized by the CYP3A4 enzyme but is affected by OATP1B1 transporter inhibition, such as by Clarithromycin. Regulatory documents also note that the interaction risk is formally increased by underlying patient factors, including renal impairment, hepatic impairment, age over 70, and alcohol abuse.

Dual Mechanism: Cholesterol Synthesis and Fat Catabolism

The Pravastatin component exerts its action in the liver by acting as a competitive inhibitor of the enzyme HMG-CoA Reductase.

This blockade of the rate-limiting step in hepatic cholesterol production leads to a compensatory upregulation of LDL-Receptors on hepatocyte surfaces. The physiological consequence is an enhanced hepatic uptake of circulating Low-Density Lipoprotein Cholesterol (LDL-C) particles from the plasma.

Simultaneously, the Fenofibrate component exerts its action through the activation of the nuclear receptor Peroxisome Proliferator-Activated Receptor alpha (PPAR- alpha). This binding initiates transcriptional changes that increase the activity of Lipoprotein Lipase (LPL) and reduce the level of LPL inhibitors. The core physiological effect is the enhanced breakdown and systemic catabolism of Triglyceride-Rich Lipoproteins (TRLs), such as VLDL, contributing to the lowered concentration of plasma triglycerides. The fixed-dose combination engages two distinct, mechanistically independent pathways of lipid metabolism, resulting in a coordinated modulation of multiple lipoprotein concentrations.

How to Use Pravafenix (Fenofibrate/Pravastatin) — Administration Guidelines

Pravafenix is an oral fixed-dose combination medicine used according to a standardized administration regimen. The regimen is used as an adjunctive measure to ongoing lifestyle modifications, including a standard cholesterol-lowering diet.

---

Administration Scope

Feature	Guideline
Route of administration:	Oral (by mouth).
Dosing schedule:	One 40 mg/160 mg hard capsule per day (40 mg pravastatin/160 mg fenofibrate).
Timing in relation to meals:	Must be taken with food, specifically during the evening meal.
Preparation requirements:	The hard capsule is swallowed whole with no dilution or other preparation necessary.

---

Procedural Conditions

Administration occurs under specific pre-conditions and duration rules. Before treatment begins, secondary causes of combined dyslipidaemia are assessed, and the patient is placed on and continuously follows a standard diet.

Treatment is part of a long-term plan where response is monitored by determining serum lipid values. If an adequate therapeutic response has not been achieved within three months of treatment initiation, treatment is typically discontinued.

---

Population-Specific Rules

Specific usage parameters apply based on patient age and organ function. The combination is not recommended for the paediatric population (individuals under 18 years of age). For older adults (65 years and over), starting treatment requires a prior evaluation of renal function. The medicine is contraindicated for use in patients with moderate-to-severe renal impairment or severe hepatic impairment.

Pravafenix (Fenofibrate/Pravastatin): Recent Clinical Evidence

---

Clinical Rationale for Combination Therapy

The fixed-dose combination of fenofibrate and pravastatin was developed to address mixed dyslipidemia—a condition often characterized by elevated triglycerides and low HDL-C (high-density lipoprotein cholesterol) in addition to high LDL-C (low-density lipoprotein cholesterol). Pravastatin, a statin, primarily works to lower LDL-C, while fenofibrate, a fibrate, is known for its action in lowering triglycerides and raising HDL-C.

Overview of Key Research

Clinical trials have investigated the efficacy and safety of co-administering these two agents. A major focus of research has been to determine whether the combination provides benefits in comprehensive lipid management beyond the use of either agent alone in this specific patient population.

• Lipid Profile Results: Studies assessed changes in the full lipid panel. Results indicate that the combination significantly reduced LDL-C and triglycerides, while also increasing HDL-C compared to baseline levels in participants with mixed dyslipidemia.

• Cardiovascular Events: Research has explored the relationship between this combination therapy and major cardiovascular events in high-risk patients. While individual components have established roles, evidence remains limited on the incremental long-term benefit of the fixed-dose combination in reducing overall mortality or morbidity when compared to standard single-agent therapy.

Safety and Tolerability

Research has confirmed the safety profile of the fixed-dose combination is generally consistent with the known profiles of the individual components. The combination was assessed for common side effects, with particular attention paid to the potential for muscle-related symptoms (myopathy) and effects on liver function. The reported incidence of severe adverse events in the studied populations has been low, though monitoring of liver enzymes and muscle symptoms remains a standard practice for patients receiving this type of therapy.

Key Studies & References

1. Comparison of the safety of statin monotherapy and coadministration with fenofibrate in patients with mixed hyperlipidemia: a meta-analysis

Common questions about Pravafenix (Fenofibrate/Pravastatin) (FAQ)

---

Q: What is the typical starting dosage for Pravafenix?

Official administration documents describe the product as a fixed-dose combination available as one hard capsule.

The product is indicated for use in adults whose bad cholesterol (LDL-C) is already adequately controlled on pravastatin 40 , mg monotherapy.

---

Q: If I miss a dose of Pravafenix, what should I do?

Regulatory guidance for the component medicines indicates against taking a double dose to try and make up for a forgotten dose.

Instead, it is suggested that treatment be resumed with the next scheduled daily dose as originally planned.

---

Q: What happens if I stop taking Pravafenix suddenly?

Official product information does not detail the consequences of sudden cessation.

However, the label states that therapy must be discontinued immediately if marked elevations in muscle enzymes (creatine kinase) or liver enzymes (transaminases) are confirmed. Discontinuation is also appropriate if an adequate therapeutic response is not achieved within three months.

---

Q: How long does it typically take for Pravafenix to start lowering my lipid levels?

Official information notes that a reduction of serum lipid levels usually follows treatment with Pravafenix.

Your response is monitored over time. If an adequate therapeutic response is not achieved within three months of treatment initiation, official guidelines state that discontinuation is appropriate.

---

Q: What should I do if I accidentally take too much Pravafenix (an overdose)?

Official product information on overdose management notes that treatment is generally symptomatic and supportive.

There is no specific antidote. Due to the way the fenofibrate component binds to proteins in the blood, special blood filtration procedures are not expected to be useful in removing the drug from the bloodstream.

---

Q: Can I drink alcohol while I am being treated with Pravafenix?

Regulatory caution is noted for patients with a history of alcohol abuse or heavy consumption, as this is associated with an increased risk of muscular toxicity and liver issues.

This is because underlying patient factors like excessive alcohol consumption can increase the formal interaction risk with the medicine.

---

Q: How long will I need to keep taking Pravafenix?

The administration is established as part of a long-term plan to manage high blood lipid levels.

There is no set maximum duration of treatment. The need for continued therapy is regularly assessed by checking your serum lipid values to ensure the medicine is providing an adequate benefit.

Official Storage and Disposal Guidelines

Storage Requirement	Regulatory Statement
Temperature	No special temperature storage conditions are required.
Container & Protection	Must be kept in the original package (blister) to protect the hard capsules from moisture.
Child Safety	Must be stored out of the sight and reach of children.
Disposal Rule	Unused or expired product must not be thrown into wastewater or household waste.
Disposal Method	Waste material must be disposed of in accordance with local requirements for medicinal products.

These guidelines establish the mandatory conditions for maintaining the stability of Pravafenix throughout its labeled shelf-life. The regulatory mandate ensures the medicine remains protected from environmental factors like moisture by requiring use of the sealed original packaging. Furthermore, official instructions prohibit disposal through household trash or water systems, requiring instead that the product be returned or discarded through recognized local pharmaceutical waste channels.